查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529867

生物标记测试服务市场规模、份额、趋势分析报告：按服务、按类型、按最终用途、按地区、细分市场预测，2024-2030 年

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Type (Molecular Biomarkers, Cellular Biomarkers), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

生物标记测试服务市场成长与趋势：

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球生物标记检测服务市场规模将达到 10.565 亿美元，2024 年至 2030 年复合年增长率为 8.46%。

药物研发投资的增加、癌症治疗中对精准医学的需求增加、感染疾病和慢性疾病负担的增加推动了生物标记测试的需求，这些是推动市场成长的主要因素。

过去五年来，临床试验持续增加。例如，根据ClinicalTrials.gov的数据，2018年註册的临床试验超过262,298项，截至2022年9月，註册的临床试验超过399,518项。由于临床研究资金的增加，预计未来几年临床试验将会改善。预计这将增加对药物发现研究活动的需求，并支持大流行后时期对生物标记测试的需求。

FDA对使用生物标记的药物的核准率逐年上升。例如，2016年，超过26项使用生物标记进行医学测试的临床试验获得FDA核准，2019年，FDA核准了36项使用生物标记进行医学测试的临床试验。临床试验现在需要生物标记相关资料来进行药物核准，因为它们提供了有关药物如何在体内发挥作用的信息，从而加快了药物核准过程。因此，预计在预测期内对生物标记测试的需求将会增加。

各种生物製药公司正在努力透过生物标记测试来提高癌症患者的诊断率。例如，2021年4月，生物製药公司安进推出了生物标记辅助计画。根据该计划，为转移性（IV 期）非小细胞肺癌（NSCLC）患者提供生物标记测试，以确认是否存在有助于标靶治疗的癌症基因生物标记。市场参与企业的这些倡议预计将支持市场成长。

根据 IQVIA 的肿瘤学趋势报告，癌症临床试验在过去十年中持续增加。例如，2011年註册了1,242项临床试验，截至2021年，已註册2,335项临床试验。由于盛行率不断增加，针对癌症的临床试验数量预计将进一步增加。使用生物标记来测试研究中药物有效性的标靶治疗的需求不断增加。未来几年癌症研究的增加预计将推动对用于癌症检测的生物标记的需求，从而支持大流行后时期的市场。

生物标誌物测试服务市场报告亮点

  • 按服务分類的生物标记检测开发和检验领域预计到 2023 年将占据最大份额，达到 45.61%。疾病诊断中对伴同性诊断的需求不断增长，预计将支持对生物标记检测开发和验证服务的需求。
  • 依最终用途划分，製药和生技公司占最大份额，2023年将达45.7%。
  • 北美地区占比最大，2023年为46.2%。技术先进的研究基础设施和公共机构不断增加的研究投资正在支持该地区的市场成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章生物标记测试服务市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
  • 生物标记测试服务市场：分析工具
  • COVID-19 影响分析

第 4 章 生物标记检测服务市场：按服务分类的估计和趋势分析

  • 细分仪表板
  • 全球生物标记检测服务市场波动分析
  • 2018-2030年全球生物标记检测服务市场规模及趋势分析（按服务）
  • 生物标记测定的开发和检验
  • 流式细胞技术
  • 其他的

第五章生物标记检测服务市场：按类型估计和趋势分析

  • 细分仪表板
  • 全球生物标记检测服务市场波动分析
  • 2018-2030年全球生物标记检测服务市场规模及趋势分析（按类型）
  • 分子生物标记
  • 细胞生物标记

第六章 生物标记检测服务市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 全球生物标记检测服务市场波动分析
  • 2018-2030 年全球生物标记测试服务市场规模和趋势分析（按最终用途）
  • 製药和生物技术公司
  • 研究所
  • CRO

第七章生物标记检测服务市场：区域估计与趋势分析

  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 2018 年至 2030 年市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018 年至 2030 年市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018 年至 2030 年市场估计与预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 印尼
    • 马来西亚
    • 新加坡
    • 台湾
  • 拉丁美洲
    • 2018 年至 2030 年市场估计与预测
    • 巴西
    • 阿根廷
    • 哥伦比亚
  • 中东/非洲
    • 2018 年至 2030 年市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 以色列

第八章 竞争格局

  • 市场参与企业分类
    • 市场领导
    • 新兴玩家
  • 服务热图分析（公司比较分析）
  • 公司简介
    • Bio Agilytix Labs
    • Eurofins Scientific
    • SGS SA.
    • Charles River Laboratories
    • LabCorp
    • Thermo Fisher Scientific Inc.（PPD, Inc.）
    • ICON Plc
    • IQVIA
    • Syneos Health
    • Intertek Group Plc
Product Code: GVR-4-68039-986-1

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1,056.5 million by 2030, registering a CAGR of 8.46% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

  • The biomarker assay development & validation segment by service was expected to hold the largest share of 45.61% in 2023. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
  • Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 45.7% in 2023, owing to the rising investment in R&D by these companies
  • North America held the largest share of 46.2% in 2023, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definition
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Detail
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives
    • 1.9.1. Objective - 1:
    • 1.9.2. Objective - 2:
    • 1.9.3. Objective - 3:
    • 1.9.4. Objective - 4:

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service Outlook
    • 2.2.2. Type Outlook
    • 2.2.3. End-Use Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for Biomarker Testing for Cancer Detection
      • 3.2.1.2. Increasing R&D Activities
      • 3.2.1.3. Growing Burden of Chronic and Infectious Diseases Supporting Demand for Biomarker Testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Capital Investments and Lengthy Timelines for Biomarker Development
  • 3.3. Biomarker Testing Services Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Biomarker Testing Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biomarker Testing Service Market Movement Analysis
  • 4.3. Global Biomarker Testing Service Market Size & Trend Analysis, by services, 2018 to 2030 (USD Million)
  • 4.4. Biomarker Assay Development & Validation
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Flow Cytometry
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Testing Services Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biomarker Testing Services Market Movement Analysis
  • 5.3. Global Biomarker Testing Services Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Molecular Biomarkers
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Cellular Biomarkers
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Testing Services Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biomarker Testing Services Market Movement Analysis
  • 6.3. Global Biomarker Testing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical and Biotechnology Companies
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Research Institutes
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. CROs
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Scenario
      • 7.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.8. Indonesia
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Scenario
      • 7.6.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.9. Malaysia
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Competitive Scenario
      • 7.6.9.3. Regulatory Scenario
      • 7.6.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.10. Singapore
      • 7.6.10.1. Key Country Dynamics
      • 7.6.10.2. Competitive Scenario
      • 7.6.10.3. Regulatory Scenario
      • 7.6.10.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.6.11. Taiwan
      • 7.6.11.1. Key Country Dynamics
      • 7.6.11.2. Competitive Scenario
      • 7.6.11.3. Regulatory Scenario
      • 7.6.11.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.7.4. Colombia
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 7.8.6. Israel
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Scenario
      • 7.8.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 8.3. Company Profiles
    • 8.3.1. Bio Agilytix Labs
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Eurofins Scientific
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. SGS SA.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Charles River Laboratories
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. LabCorp
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Thermo Fisher Scientific Inc. (PPD, Inc.)
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. ICON Plc
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. IQVIA
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Syneos Health
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Intertek Group Plc
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List oList of Tables
  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 4. Global Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 5. Global Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 6. Global Biomarker Testing Services, by Region, 2018 - 2030 (USD Million)
  • Table 7. North America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 8. North America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 9. North America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 10. North America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 11. U.S. Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 12. U.S. Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 13. U.S. Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 14. Canada Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 15. Canada Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 16. Canada Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 17. Mexico Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 18. Mexico Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 19. Mexico Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 20. Europe Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 21. Europe Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 22. Europe Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 23. Europe Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 24. Germany Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 25. Germany Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 26. Germany Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 27. UK Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 28. UK Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 29. UK Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 30. France Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 31. France Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 32. France Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 33. Italy Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 34. Italy Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 35. Italy Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 36. Spain Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 37. Spain Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 38. Spain Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 39. Denmark Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 40. Denmark Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 41. Denmark Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 42. Sweden Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 43. Sweden Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 44. Sweden Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 45. Norway Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 46. Norway Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 47. Norway Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 52. China Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 53. China Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 54. China Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Japan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 56. Japan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 57. Japan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 58. India Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 59. India Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 60. India Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 61. South Korea Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 62. South Korea Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 63. South Korea Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 64. Australia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 65. Australia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 66. Australia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 67. Thailand Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 68. Thailand Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 69. Thailand Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 70. Indonesia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 71. Indonesia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 72. Indonesia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 73. Malaysia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 74. Malaysia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 75. Malaysia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 76. Singapore Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 77. Singapore Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 78. Singapore Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 79. Taiwan Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 80. Taiwan Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 81. Taiwan Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 82. Latin America Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 83. Latin America Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 84. Latin America Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 85. Latin America Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 86. Brazil Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 87. Brazil Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 88. Brazil Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 89. Argentina Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 90. Argentina Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 91. Argentina Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 92. Middle East & Africa Biomarker Testing Services, by Country, 2018 - 2030 (USD Million)
  • Table 93. Middle East & Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 94. Middle East & Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 95. Middle East & Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 96. South Africa Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 97. South Africa Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 98. South Africa Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 99. Saudi Arabia Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 100. Saudi Arabia Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 101. Saudi Arabia Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 102. UAE Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 103. UAE Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 104. UAE Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 105. Kuwait Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 106. Kuwait Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 107. Kuwait Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)
  • Table 108. Israel Biomarker Testing Services, by Service, 2018 - 2030 (USD Million)
  • Table 109. Israel Biomarker Testing Services, by Type, 2018 - 2030 (USD Million)
  • Table 110. Israel Biomarker Testing Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biomarker Testing Services, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biomarker Testing Services, for Biomarker Assay Development & Validation, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biomarker Testing Services, for Flow Cytometry, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biomarker Testing Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biomarker Testing Services, for Molecular Biomarkers, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biomarker Testing Services, for Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biomarker Testing Services, for CROs, 2018 - 2030 (USD Million)
  • Fig. 18 Regional Outlook, 2023 & 2030
  • Fig. 19 North America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Canada Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Mexico Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Europe Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Germany Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 UK Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 France Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Italy Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Spain Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Denmark Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sweden Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Norway Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Asia Pacific Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Japan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 China Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 India Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Australia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 South Korea Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Thailand Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Indonesia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Malaysia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Singapore Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Taiwan Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Argentina Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East and Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Israel Biomarker Testing Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)